TNO Extends Licensing Agreement with Genego

GeneGo, Inc. has announced that TNO, The European Nutrigenomics Organisation (NUGO) Consortium and The Netherlands Nutrigenomics Consortium (NGC) have extended their agreement with Genego. Further, the recently established Netherlands Toxicogenomics Centre (NTC) will soon acquire MetaCore and MetaDrug for applications in toxicogenomics.

This provides over 20 universities in Europe with access to MetaCore. GeneGo has a Rodent version of MetaCore with rat and mouse genes, protein complexes and interactions. This is the first species specific database which is not derived from ortholog matching. This level of detail is crucial for nutritionists and toxicologists who deduce human efficacy and toxicity based on animal models data.

“We have established a close relationship with TNO over the years”, said Julie Bryant, GeneGo’s VP of Business development. “The projects we collaborate on include a study on cholesterol diet and drug effects on atherosclerosis and nutrigenomics. TNO is also using GeneGo products as part of their tox service offerings. We look forward to further collaborations and more publications.”

RELATED ARTICLES

Despite decades of research, treatments that can target a common mutation in the most frequently diagnosed type of pancreatic cancer have remained elusive. Now, researchers report they have discovered a mechanism of resistance to a treatment they’d identified as promising.

Patients with human papillomavirus (HPV)-positive throat cancer should carry on receiving chemotherapy rather than switching to a targeted cancer drug during curative radiotherapy, new clinical trial results have shown.